A phase II trial has found found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis, a painful complication that is common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published by Olson et al in the Journal of Clinical Oncology.
Infusion of T cells targeting BKV resulted in rapid responses, with 67.7% of patients seeing a complete or partial improvement in symptoms after 14 days. This increased to 81.6% of patients after 28 days postinfusion. No cases of grade 3 or grade 4 graft-vs-host disease or other infusion-related toxicities occurred.
Katy Rezvani, MD, PhD
“BKV-associated hemorrhagic cystitis is an incredibly painful condition that causes significant morbidity in patients and can lead to worse cancer outcomes in the long term. Unfortunately, there are no effective treatments available,” said corresponding study author Katy Rezvani, MD, PhD, Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center. “We were driven to develop this therapy to provide a better option for these patients, and this has emerged as a safe and effective therapy for patients at MD Anderson based on these results.”
BKV is a human polyomavirus acquired by most people in early childhood, Dr. Rezvani explained. Held in check by the immune system, BKV typically remains inactive in the cells lining the urinary tract, including the kidney, bladder, and ureters.
Allogeneic stem cell transplants, in which stem cells come from a matched donor, require patients to be given therapies to suppress the immune system and prevent rejection. However, this also can trigger the BKV to begin reproducing and cause severe cystitis, which can result in hospitalization. The antiviral agent cidofovir has been used as a treatment but is associated with significant toxicities.
Developing Antiviral T-Cell Therapies
Recognizing that these viral infections can profoundly impact patient recovery, Dr. Rezvani and her research team led the development of antiviral T-cell therapies. Beginning with blood samples taken from healthy donors, the research team is able to isolate T cells and grow them to specifically recognize and target a variety of antigens found on the BKV. These cells are expanded in a good manufacturing practice laboratory. From each donor, the team can manufacture anywhere from 20 to 50 doses of antiviral T cells, which are stored until needed, Dr. Rezvani said.
In a previous trial published in The New England Journal of Medicine, these researchers showed that BKV-specific T cells can effectively treat infection with the JC virus, a genetically similar polyomavirus that causes progressive multifocal leukoencephalopathy, a rare and often fatal brain infection.
The current trial enrolled a total of 59 MD Anderson patients experiencing BKV hemorrhagic cystitis following an allogeneic stem cell transplant. Patients had a median age of 47 and were being treated for a variety of hematologic conditions, the most common being acute myeloid leukemia. Women accounted for 40.7% of participants and men for 59.3%. Among trial participants, 55.9% (n = 33) were White, 18.6% (n = 11) were Hispanic, 15.3% (n = 9) were Black, 6.8% (n = 4) were Middle Eastern, and 3.4% (n = 2) were Asian.
Patients received a single infusion of partially human leukocyte antigen–matched T cells, with the option to receive additional infusions every 2 weeks if needed. Following infusion, the researchers did not observe any side effects that were likely attributed to the antiviral T cells. No infusion-related toxicities, low blood cell counts, or graft failures were found. Several patients developed delayed cases of low-grade graft-vs-host disease in the weeks and months following treatment, which were well within the expected rates of graft-vs-host disease for these patients early after allogeneic stem cell transplant, Dr. Rezvani explained.
The median time for patients to have a partial response was 14 days and the median time to complete response was 21 days. The estimated probability of achieving a complete response was nearly 70% by day 45, indicating continuous activity of the infused cells. Responses were durable, and no patients saw their symptoms return after a previously achieved response. After studying participants on the trial, the researchers determined that expansion of the infused T cells was positively correlated with patient responses.
“We are extremely encouraged by the safety of this treatment and the rapid responses we’ve seen in the majority of patients,” said Dr. Rezvani. “Because this approach is so safe, we’ve been able to offer this treatment as an outpatient procedure as soon as patients begin developing symptoms. This has been life-changing for the patients we’ve been able to treat so far.”
In the future, the researchers aim to validate these findings in a multi-institutional study and bring this treatment option to many more patients in need.
Disclosure: For full disclosures of the study authors, visit ascopubs.org.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.